Feedback
We’d love to hear your feedback on this activity. It helps us to continually improve our products.
CORRECT!
Faculty & Disclosures
Dr Laura Mertens
Netherlands Cancer Institute, Amsterdam, The Netherlands
Dr Laura Mertens is a urologist at the Netherlands Cancer Institute in Amsterdam, The Netherlands. read more
Dr Merten’s main expertise is clinical oncological urology, particularly focusing on bladder cancer, and research on optimizing bladder cancer imaging. Her long-term career goal is to improve the outcome of patients with invasive bladder cancer.
Dr Mertens’s career in urology started with a PhD in urology/surgical oncology at the Netherlands Cancer Institute. Her research, mentored by Prof. Simon Horenblas and Dr Bas van Rhijn, focused on enhancing imaging and treatment of bladder cancer, including several international collaborations on the value of FDG-PET/CT for preoperative staging.
After her PhD, Dr Mertens did her clinical training in urology at Amsterdam University Medical Center. Subsequently, she did a clinical fellowship in oncological urology at the Netherlands Cancer Institute (Prof. Henk van der Poel and Dr Bas van Rhijn). She is involved in the European Association of Urology Muscle-Invasive Bladder Cancer Guidelines panel and the Young Academic Urologists Working Group Urothelial.
Dr Laura Mertens discloses: Advisory board or panel fees from Janssen and Merck (relationships terminated). Grants/research support from Pfizer.
Prof. Thomas Powles
Barts Cancer Centre, London, UK
Prof. Thomas Powles is Director of the Barts Cancer Centre, one of the UK’s largest cancer centres, and a professor of genitourinary oncology at the Queen Mary University of London, UK. read more
Prof. Powles has led a number of clinical trials and translational oncology projects that have appeared in major journals. He has had a key role in the development of biomarkers and new drug strategies in genitourinary cancer, including multiple EMA and FDA approvals. In 2023, Prof. Powles was named in ‘Nature’s 10’, a list of the most influential global scientists.
Prof. Powles has over 300 peer-reviewed publications. He has presented data at plenary sessions at major meetings and received the bladder cancer award at the American Society of Clinical Oncology Genitourinary Cancers Symposium in 2018. Prof. Powles hosts multiple podcasts and has an active role on social media, with over 10,000 followers on X.
Prof. Powles leads the European Society for Medical Oncology (ESMO) guidelines for renal and bladder cancer and was the track chair for non-prostate genitourinary cancer in 2021. He has previously been part of the steering committee for the educational and scientific tracks for ESMO meetings, including co-chairing the ESMO Immuno-Oncology Congress from 2019 to 2021.
Prof. Thomas Powles discloses: Advisory board or panel fees from Astellas, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Ipsen, Johnson & Johnson, Merck/Merck Sharp & Dohme, Merck Serono, Novartis, Pfizer, Roche and Seattle Genetics. Consultancy fees from Astellas, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Gilead, Incyte, Ipsen, Johnson & Johnson, Mashup, Merck/Merck Sharp & Dohme, Merck Serono, Novartis, Pfizer, Roche and Seattle Genetics. Grants/research support fees from Astellas, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Ipsen, Johnson & Johnson, Merck/Merck Sharp & Dohme, Merck Serono, Novartis, Pfizer, Roche and Seattle Genetics.
Ms Lindsay Diamond
Icahn School of Medicine at Mount Sinai, NY, USA
Ms Lindsay Diamond is an advanced practitioner provider manager at the Icahn School of Medicine at Mount Sinai and a nurse practitioner at Mount Sinai Hospital, New York, NY, USA. She is also an adjunct professor at the Phillips School of Nursing at Mount Sinai. read more
As a nurse practitioner, Ms Diamond coordinates the care of patients with genitourinary (GU) cancers throughout the interdisciplinary system and is the clinical nurse practitioner and sub-investigator on all clinical trials in this area.
Since 2022, Ms Diamond has been a guest lecturer at the New York University Rory Meyers College of Nursing, where she lectures on GU cancers each semester. She was nominated for the CURE® 2022 Extraordinary Healer® Award for Oncology Nursing.
Ms Lindsay Diamond discloses: Speaker’s bureau fees from Exelixis.
